JB Capital LLC boosted its stake in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 597.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,384 shares of the company's stock after acquiring an additional 8,038 shares during the quarter. JB Capital LLC's holdings in Elevance Health were worth $3,462,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in ELV. Cypress Wealth Services LLC lifted its position in Elevance Health by 3.5% during the 3rd quarter. Cypress Wealth Services LLC now owns 679 shares of the company's stock worth $353,000 after buying an additional 23 shares in the last quarter. Atomi Financial Group Inc. boosted its position in Elevance Health by 4.2% during the third quarter. Atomi Financial Group Inc. now owns 615 shares of the company's stock valued at $320,000 after purchasing an additional 25 shares during the last quarter. Lifeworks Advisors LLC grew its stake in Elevance Health by 2.5% in the third quarter. Lifeworks Advisors LLC now owns 1,037 shares of the company's stock valued at $539,000 after purchasing an additional 25 shares in the last quarter. Catalyst Financial Partners LLC raised its stake in shares of Elevance Health by 2.9% during the 3rd quarter. Catalyst Financial Partners LLC now owns 918 shares of the company's stock worth $477,000 after purchasing an additional 26 shares in the last quarter. Finally, Fullcircle Wealth LLC boosted its holdings in shares of Elevance Health by 1.5% in the 3rd quarter. Fullcircle Wealth LLC now owns 1,743 shares of the company's stock valued at $906,000 after buying an additional 26 shares during the last quarter. 89.24% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of analysts have commented on the stock. Morgan Stanley cut their price target on shares of Elevance Health from $643.00 to $551.00 and set an "overweight" rating for the company in a research note on Wednesday, October 23rd. Argus reiterated a "hold" rating and set a $405.40 price target on shares of Elevance Health in a report on Wednesday, January 29th. StockNews.com upgraded Elevance Health from a "hold" rating to a "buy" rating in a research note on Tuesday. Cantor Fitzgerald reiterated an "overweight" rating and set a $485.00 target price on shares of Elevance Health in a research note on Friday, January 24th. Finally, TD Cowen dropped their price target on Elevance Health from $589.00 to $484.00 and set a "buy" rating on the stock in a research note on Monday, October 21st. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $517.03.
Get Our Latest Stock Analysis on ELV
Elevance Health Price Performance
Shares of NYSE ELV traded up $0.15 during mid-day trading on Wednesday, reaching $402.13. The company had a trading volume of 1,205,358 shares, compared to its average volume of 1,776,789. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.50 and a current ratio of 1.45. Elevance Health, Inc. has a one year low of $362.21 and a one year high of $567.26. The firm has a market cap of $93.26 billion, a price-to-earnings ratio of 15.70, a PEG ratio of 1.19 and a beta of 0.83. The business's 50-day simple moving average is $386.46 and its 200 day simple moving average is $455.31.
Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings results on Thursday, January 23rd. The company reported $3.84 EPS for the quarter, topping analysts' consensus estimates of $3.80 by $0.04. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. On average, research analysts predict that Elevance Health, Inc. will post 34.07 earnings per share for the current fiscal year.
Elevance Health Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 25th. Shareholders of record on Monday, March 10th will be paid a dividend of $1.71 per share. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.70%. The ex-dividend date of this dividend is Monday, March 10th. This is a boost from Elevance Health's previous quarterly dividend of $1.63. Elevance Health's payout ratio is presently 25.46%.
Elevance Health Profile
(
Free Report)
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
See Also
Before you consider Elevance Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.
While Elevance Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
